Table of Contents
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant toRule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Commission FileNumber: 001-38757
For the month of January 2019
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho2-Chome
Chuo-ku,Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under coverForm 20-F orForm 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(7): ☐
Table of Contents
Information furnished on this form:
Exhibit Number | ||
1. | (English Translation) Extraordinary Report of January 16, 2019 |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||
Date: January 16, 2019 | By: | /s/ Takashi Okubo | ||||
Takashi Okubo | ||||||
Global Head of Investor Relations |
Table of Contents
—1—
Table of Contents
1. | Reason for Submitting the Extraordinary Report |
Takeda Pharmaceutical Company Limited (the “Company”) has submitted the Extraordinary Report pursuant to Article24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance concerning Disclosure of Corporate Affairs, etc. to report on resolution that resulted in change in specified subsidiaries.
2. | Details of the Extraordinary Report |
(1) Outline of specified subsidiaries
Takeda Europe Holdings B.V. | ||
(a) Company name | Takeda Europe Holdings B.V. | |
(b) Headquarters | Jupiterstraat 250, 2132 HK Hoofddorp, Netherlands | |
(c) Name of representatives | Manoj Bhojwani, Remco van Rhoon | |
(d) Capital | EUR 280 million | |
(e) Description of business | Shareholding of Takeda group entities in Europe | |
Takeda A/S | ||
(a) Company name | Takeda A/S | |
(b) Headquarters | Dybendal Alle 10, 2630 Taastrup, Denmark | |
(c) Name of representatives | Patrick Forsell | |
(d) Capital | EUR 134 thousand | |
(e) Description of business | Shareholding of Takeda group entities in Europe |
(2) Number of votes held prior to and after liquidation
Takeda Europe Holdings B.V. | ||
(a) Number of votes | ||
Before liquidation | 2,801,795 votes (of which 0 votes owned indirectly) | |
After liquidation | 0 votes | |
(b) Voting rights ownership ratio | ||
Before liquidation | 100.0 % (of which 0 shares owned indirectly) | |
After liquidation | 0.0 % | |
Takeda A/S | ||
(a) Number of votes | ||
Before liquidation | 13,362,814 votes (of which 3,195,652 votes owned indirectly) | |
After liquidation | 0 votes | |
(b) Voting rights ownership ratio | ||
Before liquidation | 100.0 % (of which 23.9 % owned indirectly) | |
After liquidation | 0.0 % |
(3) Reason for change and date of liquidation
(a) Reason for change |
The Company has decided to liquidate Takeda Europe Holdings B.V. and Takeda A/S which are specified subsidiaries. |
(b) Date of liquidation |
The administrative processes of liquidation will commence in due course in compliance with local regulations, however, the date of completion cannot be determined yet. |
—2—